These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

137 related items for PubMed ID: 2068563

  • 21.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23. Effects of defibrotide in patients with chronic deep insufficiency. The PROVEDIS study.
    Coccheri S, Andreozzi GM, D'Addato M, Gensini GF, PROVEDIS Study Group.
    Int Angiol; 2004 Jun; 23(2):100-7. PubMed ID: 15507885
    [Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25. Defibrotide: properties and clinical use of an old/new drug.
    Pescador R, Capuzzi L, Mantovani M, Fulgenzi A, Ferrero ME.
    Vascul Pharmacol; 2013 Jun; 59(1-2):1-10. PubMed ID: 23680861
    [Abstract] [Full Text] [Related]

  • 26. Baseline plasma fibrinolysis and its correlation with clinical manifestations in patients with Raynaud's phenomenon.
    Lau CS, McLaren M, Mackay I, Belch JJ.
    Ann Rheum Dis; 1993 Jun; 52(6):443-8. PubMed ID: 8323396
    [Abstract] [Full Text] [Related]

  • 27. The pharmacology and clinical pharmacology of defibrotide: a new profibrinolytic, antithrombotic and anti-platelet substance.
    Ulutin ON, Balkuv-Ulutin S, Ugur MS, Ulutin T, Ozsoy Y, Cizmeci G.
    Adv Exp Med Biol; 1990 Jun; 281():429-38. PubMed ID: 2102624
    [Abstract] [Full Text] [Related]

  • 28. Defibrotide. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in vascular disorders.
    Palmer KJ, Goa KL.
    Drugs; 1993 Feb; 45(2):259-94. PubMed ID: 7681375
    [Abstract] [Full Text] [Related]

  • 29. Intravenous iloprost treatment of Raynaud's phenomenon and ischemic ulcers secondary to systemic sclerosis.
    Wigley FM, Seibold JR, Wise RA, McCloskey DA, Dole WP.
    J Rheumatol; 1992 Sep; 19(9):1407-14. PubMed ID: 1279170
    [Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32. Defibrotide reduces monocyte PAI-2 and procoagulant activity.
    Abbate R, Gori AM, Martini F, Attanasio M, Comeglio P, Giusti B, Zarone N, Francalanci I, Prisco D, Gensini GF.
    Semin Thromb Hemost; 1995 Sep; 21(2):245-50. PubMed ID: 7660147
    [Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36. A double blind placebo controlled crossover randomized trial of diltiazem in Raynaud's phenomenon.
    Rhedda A, McCans J, Willan AR, Ford PM.
    J Rheumatol; 1985 Aug; 12(4):724-7. PubMed ID: 3903157
    [Abstract] [Full Text] [Related]

  • 37. Prevention of deep venous thrombosis in orthopedic surgery: effects of defibrotide.
    Zanasi R, Fioretta G, Ciocia G, Bergonzi M.
    Clin Ther; 1988 Aug; 10(4):350-7. PubMed ID: 3079005
    [Abstract] [Full Text] [Related]

  • 38. Efficacy evaluation of prostaglandin E1 against placebo in patients with progressive systemic sclerosis and significant Raynaud's phenomenon.
    Bartolone S, Trifiletti A, De Nuzzo G, Scamardi R, Larosa D, Sottilotta G, Raffa A, Barbera N.
    Minerva Cardioangiol; 1999 May; 47(5):137-43. PubMed ID: 10479851
    [Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 7.